Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. - Wikidata - wikimedia - TriplyDB

Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

http://www.wikidata.org/entity/Q44085049

about

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.Loss of primary cilia occurs early in breast cancer development.Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro.Met and its ligand HGF are associated with clinical outcome in breast cancer.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population.

P2860

Q26748581-0CD35AC9-AE0C-4485-AF63-8B075830504B Q28087523-2AA3EB14-2F55-494D-8A3C-E2D97C026C3F Q33414349-D773F624-E309-4AF8-96A1-4F6D56215FCD Q33566693-2F61AB2A-84F6-46A5-BE89-1C4753B5D5DB Q33762003-0FBC8D26-32BD-46E9-B6D3-37BD4032FB90 Q33827521-83D419C8-8D28-4831-B363-F58ED5370CD7 Q33873330-FF7D47D0-F781-4FE7-B413-0E9D02F40681 Q33880064-CAA5AA08-6424-405F-A7CC-517476A89F0E Q34441761-CE34B342-301B-4227-9B07-87D502F24790 Q35222611-7E268204-DD45-4AE6-BC40-2A3B81B25A03 Q35872476-93E62F6A-5EF8-402F-BB78-A693FEA2208E Q36095196-C55B7A3E-2DDF-43A0-8363-F6C216BDCE84 Q37392930-4B76590D-B8A8-48B3-8D31-5261CF25AA21 Q38647802-5C94E55F-8BC3-45A9-BDE3-2FEA744433A0 Q40858674-5856B6F4-5579-4063-8785-DC63E890414F Q41344857-A6F6BDB7-0C23-4E44-BF9F-76B274F1700A Q42373819-3425BE18-8317-403F-8B3C-E40935C56D0F Q42477466-2DCBF9E1-9717-40E7-9C55-B4CC46DC3F32 Q55278765-A5470952-B43A-4E40-AB5C-54D78D71D9DF Q55409038-EA57FC8A-C13D-4F1D-BF70-28C3AE982DBC

P2860

Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

http://www.wikidata.org/entity/Q44085049

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Cytokeratin 5/6, c-Met express ...... triple-negative breast cancer.

@en

Cytokeratin 5/6, c-Met express ...... triple-negative breast cancer.

@nl

type

label

Cytokeratin 5/6, c-Met express ...... triple-negative breast cancer.

@en

Cytokeratin 5/6, c-Met express ...... triple-negative breast cancer.

@nl

prefLabel

Cytokeratin 5/6, c-Met express ...... triple-negative breast cancer.

@en

Cytokeratin 5/6, c-Met express ...... triple-negative breast cancer.

@nl

P1433

Q44085049-914D840B-697D-4ACD-AF65-8CD9C7F74776

P1476

Q44085049-9FBC08B9-6FDD-48C1-9F91-27A27CAAF4C6

P2093

Q44085049-03A4AA02-6B68-4EBC-AEC6-4CD73C79B9E3

Q44085049-1C79EA62-B42F-4775-A7AD-92B196AF7178

Q44085049-351C7AD9-F8D8-48CA-A666-7FBDB4FBE823

Q44085049-423A7137-A8FA-4444-896B-63B815819399

Q44085049-50E0A270-40D0-4819-A52A-D64E99A21775

Q44085049-B71D61B7-4A8B-4571-B937-F61D26A5FF76

Q44085049-C970DC3B-AFEE-4696-BA60-9F1E5808002A

Q44085049-CA5F1B9F-28FF-4A0B-971F-81D943E3B236

Q44085049-CACDB9AD-AC4B-44A9-A47F-D934B49B5441

Q44085049-E7C9ABDD-1AE1-4EF6-82F9-188C08C94846

P2860

Q44085049-00F30F8B-07BA-4798-9B4B-EC28514E50AE

Q44085049-084F7BEA-4E42-43B2-8DE2-FBB54B704516

Q44085049-09FE1F5F-062A-416C-93AE-00D3335B7C15

Q44085049-0A5D5A90-0869-43D9-84FF-B7788804B9CE

Q44085049-3B2E86E9-B5C0-4084-B334-D888FCD0FAFE

Q44085049-46FDBED5-FC38-419B-9565-42C9994FB971

Q44085049-4929A913-6B99-495C-B250-6C7BFE0A81E4

Q44085049-4FD507FE-E074-4EE7-8DEB-FBFB4CD0AD79

Q44085049-5242AB2A-98DF-4659-9F57-6D30E21710BF

Q44085049-56D09955-81EF-436C-B377-524259B90A7A

P2888

Q44085049-13076FBB-14CC-4570-9C5C-B66B363B088C

P304

Q44085049-A660081C-3962-4B23-84DA-6875AB67154E

P31

Q44085049-ED528C38-5507-46ED-8E45-E24DB7A903FC

P356

Q44085049-0F1B4E16-AA51-4B62-BAC4-38A5DEBC4191

P433

Q44085049-BE98D488-9C24-4FED-AB40-1A53BAB57AC1

P478

Q44085049-F7DF5F06-79AC-4561-B0E1-8C09475C8D9A

P577

Q44085049-0B466845-7B6B-4683-90F0-E2593133A839

P698

Q44085049-87279BAB-9DAD-4F17-BEB8-C7E9FE9CDC69

P356

S12032-013-0801-7

P1433

Medical Oncology

P1476

Cytokeratin 5/6, c-Met express ...... triple-negative breast cancer.

@en

P2093

Ayse Ocak Duran

http://www.w3.org/2001/XMLSchema#string

Ersin Ozaslan

http://www.w3.org/2001/XMLSchema#string

Fatos Tekelioglu

http://www.w3.org/2001/XMLSchema#string

Ferhan Elmali

http://www.w3.org/2001/XMLSchema#string

Halit Karaca

http://www.w3.org/2001/XMLSchema#string

Hulya Akgun

http://www.w3.org/2001/XMLSchema#string

Metin Ozkan

http://www.w3.org/2001/XMLSchema#string

Mevlude Inanc

http://www.w3.org/2001/XMLSchema#string

Oktay Bozkurt

http://www.w3.org/2001/XMLSchema#string

Veli Berk

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

Repeated observation of breast tumor subtypes in independent gene expression data sets

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Gene expression profiling of breast cell lines identifies potential new basal markers.

Triple-negative breast cancer: clinical features and patterns of recurrence.

CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.

Clinical significance of morphologic characteristics in triple negative breast cancer.

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

P2888

s12032-013-0801-7

P304

801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-013-0801-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24326984

http://www.w3.org/2001/XMLSchema#string